| 1 |
Hindricks G，Potpara T，Dagres N，et al.2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the european association for cardio-thoracic surgery (EACTS)：the task force for the diagnosis and management of atrial fibrillation of the european society of cardiology (ESC) developed with the special contribution of the european heart rhythm association (EHRA) of the ESC[J]．Eur Heart J，2021，42(5)：373-498.
|
| 2 |
Atzema CL，LamK，Young C，et al.Patients with atrial fibrillation and an alternative primary diagnosis in the emergency department：a description of their characteristics and outcomes[J]．Acad Emerg Med，2013，20(2)：193-199.
|
| 3 |
Healey JS，Oldgren J，Ezekowitz M，et al.Occurrence of death and stroke in patients in 47 countries 1 year after presenting with atrial fibrillation：a cohort study[J]．Lancet，2016，388(10050)：1161-1169.
|
| 4 |
Benjamin EJ，Muntner P，Alonso A，et al.Heart disease and stroke statistics-2019 update：a report from the American Heart Association[J]．Circulation，2019，139(10)：e56-e528
|
| 5 |
Allan V，Honarbakhsh S，Casas JP，et al.Are cardiovascular risk factors also associated with the incidence of atrial fibrillation？a systematic review and field synopsis of 23 factors in 32 population-based cohorts of 20 million participants[J]．Thromb Haemost，2017，117(5)：837-850.
|
| 6 |
Feghaly J，Zakka P，London B，et al.Genetics of atrial fibrillation[J]．J Am Heart Assoc，2018，7(20)：e009884.
|
| 7 |
Boriani G，Savelieva I，Dan GA，et al.Chronic kidney disease in patients with cardiac rhythm disturbances or implantable electrical devices：clinical significance and implications for decision making-a position paper of the european heart rhythm association endorsed by the heart rhythm society and the asia pacific heart rhythm society[J]．Europace，2015，17(8)：1169-1196.
|
| 8 |
Gallagher C，Hendriks JML，Elliott AD，et al.Alcohol and incident atrial fibrillation-a systematic review and meta-analysis[J]．Int J Cardiol，2017(246)：46-52.
|
| 9 |
Ricci C，Gervasi F，Gaeta M，et al.Physical activity volume in relation to risk of atrial fibrillation. a non-linear meta-regression analysis[J]．Eur J Prev Cardiol，2018，25(8)：857-866.
|
| 10 |
Boriani G，Laroche C，Diemberger I，et al.Asymptomatic atrial fibrillation: clinical correlates，management，and outcomes in the EORP-AF pilot general registry[J]．Am J Med，2015，128(5)：509-518.e2.
|
| 11 |
Siontis KC，Gersh BJ，Killian JM，et al.Typical，atypical，and asymptomatic presentations of new-onset atrial fibrillation in the community：characteristics and prognostic implications[J]．Heart Rhythm，2016，13(7)：1418-1424.
|
| 12 |
中华医学会心电生理和起搏分会，中国医师协会心律学专业委员会，中国房颤中心联盟心房颤动防治专家工作委员会．心房颤动：目前的认识和治疗建议(2021)[J]．中华心律失常学杂志，2021，26(1)：15-88.
|
| 13 |
Shi S，Tang Y，Zhao Q，et al.Prevalence and risk of atrial fibrillation in China：a national cross-sectional epidemiological study[EB/OL]．(2021-12-06)[2022-04-01]．
URL
|
| 14 |
Zhou Z，Hu D．An epidemiological study on the prevalence of atrial fibrillation in the Chinese population of mainland China[J]．J Epidemiol，2008，18(5)：209-216.
|
| 15 |
Marrouche NF，Brachmann J，Andresen D，et al.Catheter ablation for atrial fibrillation with heart failure[J]．N Engl J Med，2018，379(5)：417-427.
|
| 16 |
Ruddox V，Sandven I，Munkhaugen J，et al.Atrial fibrillation and the risk for myocardial infarction，all-cause mortality and heart failure：a systematic review and meta-analysis[J]．Eur J Prev Cardiol，2017，24(14)：1555-1566.
|
| 17 |
Mac A，Mfa B，Dvma B，et al.Heart failure and atrial fibrillation，like fireand fury[J]．JACC Heart Fail，2019，7(6)：447-456.
|
| 18 |
Gopinathannair R，Chen LY，Chung MK，et al.Managing atrial fibrillation in patients with heart failure and reduced ejection fraction：a scientific statement from the American Heart Association[J]．Circ Arrhythm Electrophysiol，2021，14(6)：HAE0000000000000078.
|
| 19 |
Savarese G，Giugliano RP，Rosano GM，et al.Efficacy and safety of novel oral anticoagulants in patients with atrial fibrillation and heart failure：a meta-analysis[J]．JACC Heart Fail，2016，4(11)：870-880.
|
| 20 |
Filippatos G，Farmakis D．How to use beta-blockers in heart failure with reduced ejection fraction and atrial fibrillation[J]．J Am Coll Cardiol，2017，69(24)：2897-2900.
|
| 21 |
Nielsen PB，Larsen TB，Gorst-Rasmussen A，et al.β-blockers in atrial fibrillation patients with or without heart failure：association with mortality in a nationwide cohort study[J]．Circ Heart Fail，2016，9(2)：e002597.
|
| 22 |
Imamura T，Kinugawa K．Novel rate control strategy with landiolol in patients with cardiac dysfunction and atrial fibrillation[J]．ESC Heart Failure，2020，7(5)：2208-2213.
|
| 23 |
Khan MN，Jaïs P，Cummings J，et al.Pulmonary-vein isolation for atrial fibrillation in patients with heart failure[J]．N Engl J Med，2008，359(17)：1778-1785.
|
| 24 |
Macdonald MR，Connelly DT，Hawkins NM，et al.Radiofrequency ablation for persistent atrial fibrillation in patients with advanced heart failure and severe left ventricular systolic dysfunction：a randomised controlled trial[J]．Heart，2011，97(9)：740-747.
|
| 25 |
Jones DG，Haldar SK，Hussain W，et al.A randomized trial to assess catheter ablation versus rate control in the management of persistent atrial fibrillation in heart failure[J]．J Am Coll Cardiol，2013，61(18)：1894-1903.
|
| 26 |
Chen MS，Marrouche NF，Khaykin Y，et al.Pulmonary vein isolation for the treatment of atrial fibrillation in patients with impaired systolic function[J]．J Am Coll Cardiol，2004，43(6)：1004-1009
|
| 27 |
Di Biase L，Mohanty P，Mohanty S，et al.Ablation versus amiodarone for treatment of persistent atrial fibrillation in patients with congestive heart failure and an implanted device：results from the AATAC multicenter randomized trial[J]．Circulation，2016，133(17)：1637-1644.
|
| 28 |
Soulat-Dufour L，Lang S，Addetia K，et al.Restoring sinus rhythm reverses cardiac remodeling and reduces valvular regurgitation in patients with atrial fibrillation[J]．J Am Coll Cardiol，2022，79(10)：951-961.
|
| 29 |
Karelas D，Papanikolaou J，Kossyvakis C，et al.Old stuff still trending：use of propafenone as a safety net until catheter ablation in a patient with documented pre-excited atrial fibrillation and wolff-parkinson-white syndrome-a classic case report[J]．Eur Heart J Case Rep，2021，5(12)：ytab485.
|
| 30 |
Etheridge SP，Escudero CA，Blaufox AD，et al.Life-threatening event risk in children with wolff-parkinson-white syndrome：a multicenter international study[J]．JACC Clin Electrophysiol，2018，4(4)：433-444.
|
| 31 |
Gemma LW，Steinberg LA，Prystowsky EN，et al.Development of rapid preexcited ventricular response to atrial fibrillation in a patient with intermittent preexcitation[J]．J Cardiovasc Electrophysiol，2013，24(3)：347-350.
|
| 32 |
Brugada J，Katritsis DG，Arbelo E，et al.2019 ESC guidelines for the management of patients with supraventricular tachycardia the task force for the management of patients with supraventricular tachycardia of the european society of cardiology (ESC)[J]．Eur Heart J，2020，41(5)：655-720.
|
| 33 |
范西真，苏浩．预激综合征伴房颤射频消融治疗的探讨[J]．临床心电学杂志，2012，21(5)：350-352.
|
| 34 |
Hocini M，Sanders P，Deisenhofer I，et al.Reverse remodeling of sinus node function after catheter ablation of atrial fibrillation in patients with prolonged sinus pauses[J]．Circulation，2003, 108(10)：1172-1175.
|
| 35 |
Chen YW，Bai R，Lin T，et al.Pacing or ablation：which is better for paroxysmal atrial fibrillation-related tachycardia-bradycardia syndrome？[J]．Pacing Clin Electrophysiol，2014，37(4)：403-411.
|
| 36 |
Inada K，Yamane T，Tokutake K，et al.The role of successful catheter ablation in patients with paroxysmal atrial fibrillation and prolonged sinus pauses: outcome during a 5-year follow-up[J]．Europace，2014，16(2)：208-213.
|
| 37 |
时向民，王玉堂，单兆亮，等．快慢综合征心房颤动患者射频消融术后心率及窦房结功能的变化[J]．中国心血管杂志，2012，17(2)：113-116.
|
| 38 |
张舒珊，张煊赫，常栋，等．导管消融术治疗房性快速性心律失常对快慢综合征远期预后的观察[J/CD]．中国心脏起搏与心电生理杂志，2020，34(4)：350-354.
|
| 39 |
马晓烨，周晓茜，贡时雨，等．导管射频消融阵发性心房颤动合并快慢综合征的疗效观察[J]．国际心血管病杂志，2018，45(5)：292-295.
|